Evidence map›Paper›PMID 35128104›Full record

ReviewHeliyon2022

Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review.

Md Sohel, Habiba Sultana, Tayeba Sultana, Md Al Amin, Suraiya Aktar, Md Chayan Ali, Zahed Bin Rahim, Md Arju Hossain, Abdullah Al Mamun, Mohammad Nurul Amin and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Hesperetin induces apoptosis in lung squamous carcinoma cells via GInternational journal of molecular medicine · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Md SohelDepartment of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Habiba SultanaDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Tayeba SultanaDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Md Al AminDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Suraiya AktarDepartment of Biochemistry and Molecular Biology, Rajshahi University, Rajshahi, Bangladesh.
Md Chayan AliDepartment of Biotechnology and Genetic Engineering, Islamic University, Kushtia 7003, Bangladesh.
Zahed Bin RahimDepartment of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.
Md Arju HossainDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Abdullah Al MamunDepartment of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Mohammad Nurul AminDepartment of Pharmacy, Atish Dipankar University of Science and Technology, Dhaka 1230, Bangladesh.
Raju DashDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.
Mawlana Bhashani Science and Technology University · BDAtish Dipankar University of Science and Technology · BDBGC Trust University Bangladesh · BDDongguk University · KRIslamic University · BDUniversity of Rajshahi · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer has become a significant concern in the medical sector with increasing disease complexity. Although some available conventional treatments are still a blessing for cancer patients, short-and long-term adverse effects and poor efficiency make it more difficult to treat cancer patients, demonstrating the need for new potent and selective anticancer drugs. In search of potent anticancer agents, naturally occurring compounds have always been admired due to their structural diversity, where Hesperetin (HSP) may be one of the potent candidates. PURPOSE: We aimed to summarize all sources, pharmacological properties, anticancer activities of HSP against numerous cancers types through targeting multiple pathological processes, mechanism of HSP on sensitizing the current anti-cancer agents and other phytochemicals, overcoming resistance pattern and determining absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox).

methodsInformation was retrieved from PubMed, Science Direct, and Google Scholar based on some key points like Hesperetin, cancer name, anticancer resistance, nanoformulation, and ADME/Tox was determined by

resultHSP is a phytoestrogen present in citrus fruits in a high concentration (several hundred mg/kg) and exhibited anti-cancer activities through interfering at several pathways. HSP can suppress tumor formation by targeting several cellular proteins such as cell cycle regulatory, apoptosis, metastatic, tyrosine kinase, growth factor receptor, estrogen metabolism, and antioxidant-related protein.HSP has shown remarkable synergistic properties in combination therapy and has been reported to overcome multidrug cancer resistance drugs, leading to an improved defensive mechanism. These anticancer activities of HSP may be due to proper structural chemistry.

conclusionOverall, HSP showed potential anticancer activities against all cancer and possess better pharmacokinetic properties. So this phytochemical alone or combination with other agents can be an effective alternative drug for cancer treatment.

Indexed as

ADME/ToxAnticancer agentsCancerHesperetin

Identifiers

PMID35128104
PMCPMC8810372
OpenAlexW4206950364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.